AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93 $
arrow_upward
+0,96%(+0,53) 1D
13 қар., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 млрд
Avg. vol.
1,98 млн
Volume
20,00
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 млрд
Avg. vol.
1,98 млн
Volume
20,00
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
Business Insider
·
52 минут бұрын
A veteran strategist sees a split in the stock market leading to a 15% drop in the S&P 500
Reuters
·
23 минут бұрын
S&P 500, Nasdaq futures slide as Nvidia earnings, Anthropic debut loom
Benzinga
·
1 сағат бұрын
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed as Scott Bessent Presses Nvidia Over China Chi
Traders Union
·
37 минут бұрын
S&P 500 remained close to all-time highs after Nasdaq's drop, Dario Perkins notes
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Флорида, Америка Құрама Штаттары
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com